ONE Gas Q4 Earnings, Revenue Rise-March 2024-www.financetom.com

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

ONE Gas Q4 Earnings, Revenue Rise

Feb 19, 2025 2:06 PM

04:49 PM EST, 02/19/2025 (MT Newswires) -- ONE Gas ( OGS ) reported Q4 diluted earnings Wednesday of $1.34 per share, up from $1.27 a year earlier.

Analysts polled by FactSet expected $1.33.

Revenue for the quarter ended Dec. 31 was $630.7 million, up from $605.9 million a year earlier.

The company reiterated its full-year 2025 earnings guidance of $4.20 to $4.32 per share. Analysts expected $4.26.

Previous page： Digital Brands Q1 Loss Narrows, Revenue Declines; Shares Down Next page： Netflix Has Won Streaming Wars, Next Stage Will be Ad Revenue Growth, Wedbush Says

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Digital Brands Q1 Loss Narrows, Revenue Declines; Shares Down

May 20, 2024

11:49 AM EDT, 05/20/2024 (MT Newswires) -- Digital Brands Group ( DBGI ) shares were down more than 13% in recent Monday trading following its Q1 results. Earlier, the company reported a Q1 net loss of $0.46 per diluted share, narrowing from a net loss of $27.48 per share a year ago. Revenue for the quarter ended March 31 was...

Netflix Has Won Streaming Wars, Next Stage Will be Ad Revenue Growth, Wedbush Says

May 20, 2024

11:56 AM EDT, 05/20/2024 (MT Newswires) -- Netflix ( NFLX ) has a virtually insurmountable lead in the streaming wars and it's now positioning itself to increase advertising revenue, Wedbush said Monday in a note to clients. The streaming giant's rivals will likely continue to flail while trying to replicate Netflix's ( NFLX ) business model, said Wedbush analysts including...

Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise

May 20, 2024

11:57 AM EDT, 05/20/2024 (MT Newswires) -- Atara Biotherapeutics ( ATRA ) said Monday it has filed a biologics license application with the US Food and Drug Administration for tabelecleucel, or tab-cel, to treat patients with Epstein-Barr virus positive post-transplant lymphoproliferative disease. The application is supported by data from trials covering more than 430 patients with multiple life-threatening diseases, with...

$60B TAM Target: CyberArk Bolsters Machine Identity Solutions With Venafi Acquisition

May 20, 2024

CyberArk Software Ltd. ( CYBR ) inked a deal to acquire Venafi from Thoma Bravo for an enterprise value of $1.54 billion. The acquisition value includes around $1 billion in cash and about $540 million in shares. The transaction is expected to close in the second half of 2024, subject to customary closing conditions. Post closure, the company expects Venafi to add around $150 million in annual recurring revenue (ARR). Also,...